WO2017129047A1 - Drug for treating rheumatism and rheumatoid diseases - Google Patents

Abstract

The present invention provides a drug for treating rheumatism and rheumatoid diseases. The drug is glycoprotein, or a mixture of polysaccharide and protein, or polypeptide or protein.

Description

A medicine for treating rheumatoid rheumatoid Technical field

The invention relates to a medicine for treating rheumatoid rheumatoid, belonging to the technical field of medicine.

Background technique

Rheumatism and rheumatoid disease are "stubborn", "difficult", and "annoying". They are cured for a long time, and they cause repeated suffering, which makes patients suffer and headaches. According to the World Center for Disease Control, rheumatism and rheumatoid disease are another intractable disease that threatens human health after cancer. Currently, in the United States, Europe and Japan, the number of patients with rheumatism and rheumatoid disease is nearly 300 million. According to a survey in some parts of China, 85% of people over the age of 45 have different degrees of suffering from this disease, and the medical expenses paid are hundreds of millions of dollars, and there is a trend of further increase. If the treatment is delayed, it will directly threaten the heart, and some patients will have joint disability and visceral failure. Rheumatism and rheumatoid arthritis, Chinese medicine believes that the disease caused by the combination of wind and wet. Symptoms include headache, fever, slight sweat, bad wind, weight, dysuria, sore throat, and inability to flex and stretch. In addition to pain, joint lesions are accompanied by swelling and movement disorders, showing a chronic course of attack and remission. Because the patient's blood circulation is not smooth, the nutrients required by the muscles or tissues cannot be transported through the blood circulation, resulting in the lack of nutrition of the patient's muscles and accelerated aging and becoming stiff. Seriously, the muscles and blood vessels of the patients will shrink, and some patients may appear. Joint disability and visceral failure. According to relevant experts, 50% of rheumatoid and rheumatoid patients have paralysis throughout the year.

Western medicine treatment is effective, but the symptoms are not cured, the drug is relapsed, the side effects are extremely large, and it is easy to cause lifelong diseases and complications, such as damage to the nervous system, liver and kidney and other internal organs, causing endocrine disorders, stomach bleeding and other diseases, existing Chinese medicine The curative effect is single, the effect is slow, the cure rate is low, and the course of treatment is long. Therefore, there is an urgent need for drugs that effectively treat rheumatism and rheumatoid diseases.

CN200610151223.3 discloses a traditional Chinese medicine for treating tuberculosis, characterized in that the pharmaceutically active ingredient of the traditional Chinese medicine for treating tuberculosis is from 45 to 55 parts of almond, 90 to 110 parts, 90 to 110 parts, 90 to 90 parts by weight. 110 parts of glutinous rice, 90-110 parts of angelica, 45-55 parts of schisandra, 90-110 parts of medlar, 45-55 yellow essence, 90-110 parts of lily, 90-110 parts of white and 90-110 parts of ginkgo, 45-55 parts 37, 45 to 55, Chuanbei, 45 to 55 parts of glutinous rice, 380 to 420 parts of cucumber seeds and 380 to 420 parts of spinach seeds.

Summary of the invention

In order to solve the deficiencies in the prior art, the present invention provides a medicine for treating rheumatoid rheumatoid to achieve the following objects:

(1) The drug of the invention can effectively alleviate the joint pain of rheumatoid arthritis in rats, and the threshold of joint pain is significantly increased;

(2) The drug of the present invention has a significant alleviating effect on joint swelling of rat rheumatoid arthritis;

(3) The drug of the invention can increase the content of L-ENK and β-END in the hypothalamus of rats and reduce the pro-inflammatory factors IL-1β and IL-6. The secretion inhibits the synthesis and secretion of serum immunoglobulin IgG and inhibits the release of the pain stimulating factor SP.

In order to solve the above technical problems, the present invention adopts the following technical solutions:

A medicament for treating rheumatoid rheumatoid, characterized in that the medicament is a glycoprotein, or a mixture or polypeptide or protein of polysaccharide and protein, the glycoprotein comprising sugar 1-99%, protein 1-99%; The mixture of polysaccharide and protein, by weight, comprises 1-99% polysaccharide, 1-99% protein. The glycoprotein has a molecular weight of 0.2-3000 kDa;

The following are further improvements to the above technical solutions:

The drug is a marine algae glycoprotein.

The marine algae glycoprotein comprises, by weight, 1-99% sugar, 1-99% protein; a mixture of the marine algae polysaccharide and protein, including by weight, 1-99%, protein 1- 99%.

The marine algae glycoprotein has a molecular weight of 0.2-3000 kDa;

The polysaccharide and protein mixture, the polysaccharide has a molecular weight of 0.2-3000 kDa, and the protein has a molecular weight of 0.2-3000 kDa.

The drug comprises, by weight, 1-99 parts of glycoprotein and 1-25 parts of glucuronic acid.

The drug, by weight, includes 1-99 parts of marine algae glycoprotein and 1-28 parts of glucuronic acid.

The drug comprises, by weight, 1-99 parts of marine algae glycoprotein, 1-23 parts of glucuronic acid, and 3-11 parts of medlar.

The algae is one or more of cyanobacteria, green algae, red algae, gold algae, and brown algae.

The drug, by weight, includes 1-99 parts of marine algae glycoprotein, 5-13 parts of medlar, 6-14 parts of moxibustion licorice, and 1-17 parts of glucuronic acid.

The drug, by weight, includes 1-99 parts of marine algae glycoprotein, 5-13 parts of medlar, 6-14 parts of moxibustion licorice, 7-12 parts of Corydalis, and 5-10 parts of Forsythia.

The drug, by weight, includes 1-99% sugar and 1-99% protein.

The marine algae glycoprotein comprises, by weight, 1-99% sugar and 1-99% protein.

Compared with the prior art, the beneficial effects of the present invention are:

(1) The drug of the present invention can effectively alleviate the joint pain of rheumatoid arthritis in rats, and the threshold of joint pain is significantly increased. On the 25th day of the experiment, the threshold value of joint pain is 1147-1186 g, and the 30th day of the experiment, the threshold value of joint pain is 870.6. -945.7g;

(2) The drug of the present invention has a significant alleviating effect on joint swelling of rat rheumatoid arthritis. On the 25th day of the experiment, the swelling index of the right joint of the animal of the present invention was significantly decreased, being 300.3-330.5 m/kg; on the 30th day of the experiment, The right joint swelling index of animals is 231.8-270.5m/kg;

(3) The drug of the invention can increase the content of L-ENK and β-END in the hypothalamus of rats, reduce the secretion of pro-inflammatory factors IL-1β and IL-6, inhibit the synthesis and secretion of serum immunoglobulin IgG, and inhibit the pain-stimulating factor. SP release, L-ENK content It is 170.1-212.6pg/g, the β-END content is 135.6-170.6pg/g, the SP content is 60.3-67.5ng/L, the IgG content is 12.00-12.58g/L, and the IL-1β content is 0.200-0.231mg/ L, IL-6 content is 40.15-45.56 ng / L.

detailed description

The preferred embodiments of the present invention are described in the following, and the preferred embodiments described herein are intended to illustrate and explain the invention.

Embodiment 1 A medicine for treating rheumatoid rheumatoid

The drug is a marine algae glycoprotein;

The marine algae glycoprotein, which comprises 1% by weight of sugar and 99% by weight,

The molecular weight is 0.2 kDa;

The marine algae is: cyanobacteria;

The sugar is a polysaccharide;

The polysaccharide comprises: glucose, mannose, rhamnose, galactose;

The protein includes: aspartic acid, glutamic acid, glycine, arginine, lysine, serine, threonine.

Example 2 A medicament for treating rheumatoid rheumatoid

The drug is a marine algae glycoprotein;

The marine algae glycoprotein, which comprises 10% by weight of sugar and 80% by weight of protein,

The molecular weight is 13kDa;

The marine algae is: green algae;

The sugar is a polysaccharide;

The polysaccharide comprises: glucose, mannose, rhamnose, galactose;

The protein includes: aspartic acid, glutamic acid, glycine, arginine, lysine, serine, threonine.

Example 3 A medicament for treating rheumatoid rheumatoid

The drug is a marine algae glycoprotein;

The marine algae glycoprotein, comprising 20% sugar, 72% protein, by weight

The molecular weight is 5kDa;

The marine algae is: cyanobacteria;

The sugar is a polysaccharide;

The polysaccharide comprises: glucose, mannose, rhamnose, galactose;

The protein includes: aspartic acid, glutamic acid, glycine, arginine, lysine, serine, threonine.

Embodiment 4 A medicine for treating rheumatoid rheumatoid

The drug is a marine algae glycoprotein;

The marine algae glycoprotein comprises, by weight, 35% sugar, 58% protein,

The molecular weight is 120kDa;

The marine algae is: red algae;

The sugar is a polysaccharide;

The polysaccharide comprises: glucose, mannose, rhamnose, galactose;

The protein includes: aspartic acid, glutamic acid, glycine, arginine, lysine, serine, threonine.

Embodiment 5 A medicine for treating rheumatoid rheumatoid

The drug is a marine algae glycoprotein;

The marine algal glycoprotein, which comprises 60% by weight of sugar and 32% by weight,

The molecular weight is 400kDa;

The marine algae is: brown algae;

The sugar is a polysaccharide;

The polysaccharide comprises: glucose, mannose, rhamnose, galactose;

The protein includes: aspartic acid, glutamic acid, glycine, arginine, lysine, serine, threonine.

Embodiment 6 A medicine for treating rheumatoid rheumatoid

The drug is a marine algae glycoprotein;

The marine algae glycoprotein, by weight, comprises 99% sugar, 1% protein,

The molecular weight is 3000kDa;

The marine algae is: gold algae;

The sugar is a polysaccharide;

The polysaccharide comprises: glucose, mannose, rhamnose, galactose;

The protein includes: aspartic acid, glutamic acid, glycine, arginine, lysine, serine, threonine.

The glycoprotein described in the above Examples 1-6 further includes a pigment; the pigment is a natural pigment contained in the algae substance.

The above embodiments 1-6 are summarized as follows:

A medicine for treating rheumatoid rheumatoid

The drug is a glycoprotein;

The glycoprotein, by weight content, comprises 1-99% sugar, 1-99% protein;

The molecular weight is 0.2-30000 kDa;

The sugar is a polysaccharide;

The drug is a synthetic glycoprotein and a synthetic polysaccharide and protein.

The protein comprises 20 amino acids and 8 synthetic amino acids;

The preparation method of the medicine: the glycoprotein is prepared into capsules, tablets and the like according to a conventional process; the mixture of the polysaccharide and the protein is formed into capsules, tablets and the like according to a conventional process.

Example 7 Application test of a medicament for treating rheumatoid rheumatoid

experiment method:

The model rats were randomly divided into two groups: a blank control group, a model control group, and the present invention group 1-6.

A total of 8 groups, 10 in each group, except for the blank control group, began to mold on the first day of the test. The modeling method was as follows: the rats were placed in 6 ° C cold water, the water depth was 2 cm, standing for 20 minutes, and the electric fan was blown 3 Wind speed, once a day for 14 consecutive days; on the first day of modeling, each model rat was injected with 0-1 ml of complete Freund's adjuvant once in the right hind paw, and after 19 days, the invention group 1-6 The medicaments according to Examples 1-6 of the present invention were respectively administered at a dose of 3 g/day, 3 times a day for 6 consecutive days. The model control group and the blank control group were intragastrically administered with normal saline.

Determination of joint pain: The right foot joint pain of each group was measured on the 25th and 30th day of the experiment;

Determination of joint swelling: The right foot joint diameter of each group was measured by vernier caliper on the 25th and 30th day of the experiment, and calculated according to the formula: swelling index (g/kg) = joint diameter (cm) / body weight (g) × 10 ⁵

After the animals were sacrificed on the 35th day of the experiment, the thalamus, plasma, serum were separated, and the method of kit was used to determine the content of L-ENK and β-END in the hypothalamus, plasma SP content, serum immunoglobulin IgG content, serum cytokine IL- 1β content, IL-6 content.

Table 1 Effect of the drug of the present invention on joint pain in rat rheumatoid arthritis

Group	Day 25 / g	Day 30 / g
Blank control group	1545.10±90.8	1230.2±70.3
Model control group	1052.2±105.8	836.7±80.3
Example 1	1152±85.4	870.6±73.3
Example 2	1162±86.4	915.9±72.5
Example 3	1186±75.4	945.7±85.4
Example 4	1160±79.1	923.8±76.0
Example 5	1158±69.7	912.4±79.2
Example 6	1147±70.2	870.6±84.6

The medicine of the invention can effectively relieve joint pain of rheumatoid arthritis in rats, and the threshold of joint pain is significantly increased. On the 25th day of the experiment, the joint pain threshold is 1147-1186g, and the joint pain threshold is 870.6-945.7g on the 30th day of the experiment. ;

Table 2 Effect of the drug of the present invention on joint swelling of rat rheumatoid arthritis

Group	Day 25 (m/kg)	Day 30 (m/kg)
Blank control group	190.1±25.8	175.2±35.7
Model control group	350.3±21.6	300.5±34.9
Example 1	330.5±22.9	270.5±33.4
Example 2	326.1±24.1	251.4±33.5
Example 3	300.3±25.4	231.8±32.7
Example 4	312.4±23.6	241.6±28.1
Example 5	326.7±22.9	256.7±27.1
Example 6	330.2±21.7	270.1±26.5

The medicine of the invention has obvious remission effect on joint swelling of rat rheumatoid arthritis. On the 25th day of the experiment, the swelling index of the right joint of the animal of the invention group is significantly reduced, which is 300.3-330.5 m/kg; on the 30th day of the experiment, the right joint of the animal The swelling index is 231.8-270.5 m/kg.

Table 3 Effect of the drug of the present invention on L-ENK, β-END, SP, IgG, IL-1β, IL-6

[Correct according to Rule 26 13.03.2017]

The medicine of the invention can increase the content of L-ENK and β-END in the hypothalamus of rats, both of which have analgesic effect, reduce the secretion of pro-inflammatory factors IL-1β and IL-6, and inhibit the synthesis and secretion of serum immunoglobulin IgG. To inhibit the release of SP, the L-ENK content is 170.1-212.6pg/g, the β-END content is 135.6-170.6pg/g, the SP content is 60.3-67.5ng/L, and the IgG content is 12.00-12.58g. /L, IL-1β The content is 0.200-0.231 mg/L, and the IL-6 content is 40.15-45.56 ng/L.

Embodiment 8 A medicine for treating rheumatoid rheumatoid

Including 1 part of marine algae glycoprotein and 1 part of glucuronic acid;

The marine algae glycoprotein, which comprises 9% sugar and 80% protein by weight,

The molecular weight is 8kDa;

The marine algae is: chlorella;

The sugar is a polysaccharide;

The polysaccharide comprises: glucose, mannose, rhamnose, galactose;

The protein includes: aspartic acid, glutamic acid, glycine, arginine, lysine, serine, threonine.

Embodiment 9 A medicine for treating rheumatoid rheumatoid

In the same manner as in Example 8, only the ratio of marine algae glycoprotein to glucuronic acid was changed, and it was changed to:

The drug includes 24 parts of marine algae glycoprotein and 8 parts of glucuronic acid.

Embodiment 10 A medicament for treating rheumatoid rheumatoid

In the same manner as in Example 8, only the ratio of marine algae glycoprotein to glucuronic acid was changed, and it was changed to:

The drug includes 57 parts of marine algae glycoprotein and 16 parts of glucuronic acid.

Embodiment 11 A medicament for treating rheumatoid rheumatoid

In the same manner as in Example 8, only the ratio of marine algae glycoprotein to glucuronic acid was changed, and it was changed to:

The drug includes 99 parts of marine algae glycoprotein and 28 parts of glucuronic acid.

Embodiment 12 A medicament for treating rheumatoid rheumatoid

In terms of weight content, 1 part of marine algae glycoprotein, 1 part of glucuronic acid, and 3 parts of barley.

The marine algae glycoprotein, which comprises, by weight, 16% sugar, 80% protein,

The molecular weight is 12kDa;

The marine algae is: spirulina;

The sugar is a polysaccharide;

The polysaccharide comprises: glucose, mannose, rhamnose, galactose;

The protein includes: aspartic acid, glutamic acid, glycine, arginine, lysine, serine, threonine.

Embodiment 13 A medicament for treating rheumatoid rheumatoid

In the same manner as in the example 12, only the weight ratio of the marine algae glycoprotein, glucuronic acid, and barley was changed, and the change was:

The drug includes 34 parts of marine algae glycoprotein, 8 parts of glucuronic acid, and 5 parts of barley in parts by weight.

Embodiment 14 A medicament for treating rheumatoid rheumatoid

In the same manner as in the example 12, only the weight ratio of the marine algae glycoprotein, glucuronic acid, and barley was changed, and the change was:

The drug includes 59 parts of marine algae glycoprotein, 18 parts of glucuronic acid, and 8 parts of barley in parts by weight.

Embodiment 15 A medicament for treating rheumatoid rheumatoid

In the same manner as in the example 12, only the weight ratio of the marine algae glycoprotein, glucuronic acid, and barley was changed, and the change was:

The drug includes 99 parts of marine algae glycoprotein, 23 parts of glucuronic acid, and 11 parts of barley in parts by weight.

The use of the drugs of the above embodiments 8 - 15 in the treatment of rheumatism:

Using the test method described in Example 7, the modification was carried out by using the drugs described in Example 8 - Example 15, and the application effects were as follows:

Table 4 Effect of the drug of the present invention on joint pain in rat rheumatoid arthritis

Group	Day 25 / g	Day 30 / g
Blank control group	1545.10±90.8	1230.2±70.3
Model control group	1052.2±105.8	836.7±80.3
Example 8	1180±83.7	900.6±74.3
Example 9	1256±86.9	915.9±72.5
Example 10	1486±75.7	1189.7±75.4
Example 11	1260±75.1	956.8±74.0
Example 12	1188±66.7	965.4±75.3
Example 13	1252±71.2	941.6±84.8
Example 14	1435±68.4	1192.4±75.8
Example 15	1264±66.4	956.5±71.9

Table 5 Effect of the drug of the present invention on joint swelling of rat rheumatoid arthritis

Group	Day 25 (m/kg)	Day 30 (m/kg)
Blank control group	190.1±25.8	175.2±35.7
Model control group	350.3±21.6	300.5±34.9
Example 8	305.5±22.9	235.4±33.4
Example 9	306.1±23.1	231.4±30.5
Example 10	224.6±25.4	195.7±31.7
Example 11	302.4±22.6	221.6±29.2
Example 12	306.7±21.4	226.7±27.6
Example 13	316.2±22.5	230.1±26.8
Example 14	218.9±22.9	190.7±27.4
Example 15	315.8±21.5	220.7±27.8

Table 6 Effect of the drug of the present invention on L-ENK, β-END, SP, IgG, IL-1β, IL-6

Group	L-ENK	β-END	Sp	IgG	IL-1β	IL-6
Blank control group	95.2	113.2	50.2	9.54	0.115	30.56
Model control group	150.6	119.5	70.8	13.89	0.185	48.89
Example 8	190.6	185.6	57.5	11.58	0.180	35.56
Example 9	192.3	180.8	56.2	11.14	0.120	32.31
Example 10	260.7	350.6	48.3	7.6	0.200	20.15
Example 11	192.6	183.8	55.9	11.35	0.186	34.89
Example 12	190.7	189.4	56.7	10.42	0.179	35.52
Example 13	190.1	190.7	55.3	10.52	0.119	36.58
Example 14	272.4	345.9	47.6	7.8	0.185	22.68
Example 15	196.5	195.4	56.2	11.00	0.182	35.79

In Examples 8-11, only the weight ratio of marine algae glycoprotein and glucuronic acid was changed. From the experimental results, Example 10 is the most preferred embodiment;

Examples 12-15 only changed the weight ratio of marine algae glycoprotein, glucuronic acid, and strontium. From the experimental results, Example 14 is the most preferred embodiment;

Embodiment 16 A medicament for treating rheumatoid rheumatoid

In terms of weight content, it includes 1 part of marine algae glycoprotein, 5 parts of green barley, 6 parts of moxibustion licorice, and 1 part of glucuronic acid.

The marine algae glycoprotein, including 30% sugar, 50% protein, by weight

The molecular weight is 20kDa;

The marine algae is: long-leaved laver;

The sugar is a polysaccharide;

The polysaccharide comprises: glucose, mannose, rhamnose, galactose;

The protein includes: aspartic acid, glutamic acid, glycine, arginine, lysine, serine, threonine.

Embodiment 17 A medicament for treating rheumatoid rheumatoid

In the same manner as in Example 16, only the weight ratio of marine algae glycoprotein, barley, moxibustion, and glucuronic acid was changed, and the change was:

In terms of weight, it includes 47 parts of marine algae glycoprotein, 8 parts of barley, 12 parts of mojib licorice, and 15 parts of glucuronic acid.

Embodiment 18 A medicament for treating rheumatoid rheumatoid

In the same manner as in Example 16, only the weight ratio of marine algae glycoprotein, barley, moxibustion, and glucuronic acid was changed, and the change was:

In terms of weight, it includes 99 parts of marine algae glycoprotein, 13 parts of green barley, 14 parts of moxibustion licorice, and 17 parts of glucuronic acid.

Embodiment 19 A medicament for treating rheumatoid rheumatoid

In parts by weight, including 1 part of marine algae glycoprotein, 5 parts of green barley, 6 parts of moxibustion licorice, 7 parts of Corydalis, and 5 parts of Forsythia. The marine algae glycoprotein, which comprises 50% by weight of sugar and 20% by weight of protein,

The molecular weight is 200kDa;

The marine algae is: Sargassum;

The sugar is a polysaccharide;

The polysaccharide comprises: glucose, mannose, rhamnose, galactose;

The protein includes: aspartic acid, glutamic acid, glycine, arginine, lysine, serine, threonine.

Embodiment 20 A medicament for treating rheumatoid rheumatoid

In the same manner as in the embodiment 19, only the weight ratio of the marine algae glycoprotein, the barley, the mozzarella, the corydalis, and the forsythia is changed, and the change is:

In parts by weight, including 68 parts of marine algae glycoprotein, 12 parts of green barley, 11 parts of moxibustion licorice, 8 parts of Corydalis, and 9 parts of forsythia.

Embodiment 21 A medicament for treating rheumatoid rheumatoid

In the same manner as in the embodiment 19, only the weight ratio of the marine algae glycoprotein, the barley, the mozzarella, the corydalis, and the forsythia is changed, and the change is:

In parts by weight, including 99 parts of marine algae glycoprotein, 13 parts of green barley, 14 parts of moxibustion licorice, 12 parts of Corydalis, and 10 parts of forsythia.

The use of the drugs of the above embodiments 16 to 21 in the treatment of rheumatism:

The test method described in Example 7 was adopted, and the modification was carried out by using the drugs described in Example 16 to Example 21, and the application effects were as follows:

Table 7 Effect of the drug of the present invention on joint pain in rat rheumatoid arthritis

Group	Day 25 / g	Day 30 / g
Blank control group	1545.10±90.8	1230.2±70.3
Model control group	1052.2±105.8	836.7±80.7
Example 16	1280±83.7	940.6±74.9
Example 17	1536±86.9	1225.9±72.8
Example 18	1236±73.7	935.7±73.4
Example 19	1275±72.1	976.8±76.0
Example 20	1528±68.7	1227.4±77.3
Example 21	1252±72.2	971.6±82.8

Table 8 Effect of the drug of the present invention on joint swelling of rat rheumatoid arthritis

Group	Day 25 (m/kg)	Day 30 (m/kg)
Blank control group	190.1±25.8	175.2±35.7
Model control group	350.3±21.6	300.5±34.9
Example 16	298.5±20.9	200.4±23.4
Example 17	192.1±20.1	178.4±20.5
Example 18	294.6±23.4	205.7±21.7
Example 19	302.4±22.8	211.6±26.2
Example 20	195.7±21.9	176.7±25.6
Example 21	292.2±22.5	210.1±23.8

Table 9 Effect of the drug of the present invention on L-ENK, β-END, SP, IgG, IL-1β, IL-6

Group	L-ENK	β-END	Sp	IgG	IL-1β	IL-6
Blank control group	95.2	113.2	50.2	9.54	0.115	30.56
Model control group	150.6	119.5	70.8	13.89	0.185	48.89
Example 16	200.6	205.6	52.5	10.28	0.170	30.56
Example 17	302.3	380.8	45.2	7.11	0.113	20.25
Example 18	210.7	215.6	53.3	10.13	0.175	30.15
Example 19	200.6	218.8	52.9	10.03	0.176	31.89
Example 20	304.7	375.4	45.7	7.09	0.115	21.52
Example 21	211.1	216.7	53.3	10.02	0.179	31.58

In Examples 16-18, only the weight ratio of marine algae glycoprotein, barley, moxibustion, and glucuronic acid was changed. From the experimental results, Example 17 is the most preferred embodiment;

In Examples 19-21, only the weight ratio of marine algae glycoprotein, barley, moxibustion licorice, Corydalis, and forsythia was changed. From the experimental results, Example 20 is the most preferred embodiment.

Embodiment 22 A medicament for treating rheumatoid rheumatoid

In parts by weight, the following components are included:

70 parts of marine algae glycoprotein, 5 parts of valerian, 2 parts of glutinous rice grass, 3 parts of white peony, 5 parts of psyllium, 4 parts of purslane, 7 parts of puerarin, 9 parts of sage, and 10 parts of scorpion.

The marine algae glycoprotein, which comprises 8% sugar and 80% protein by weight,

The molecular weight is 10kDa;

The marine algae is: chlorella;

The sugar, in parts by weight, comprises the following components: 55 parts of glucose, 20 parts of mannose, 13 parts of rhamnose, and 8 parts of galactose;

The protein, in parts by weight, includes the following components: 13 parts of aspartic acid, 11 parts of glutamic acid, and 8 parts of glycine.

Using the test method of Example 7, the experiment was carried out using the drug of Example 22, and the results were as follows:

On the 25th day of the experiment, the joint pain threshold was 1450g, and the joint pain threshold was 1125g on the 30th day of the experiment;

On the 25th day of the experiment, the swelling index of the right joint of the animals of the present invention was significantly decreased to 212.3 m/kg; on the 30th day of the experiment, the index of swelling of the right joint of the animals was 185.6 m/kg.

The L-ENK content was 289.6 pg/g, the β-END content was 382.3 pg/g, the SP content was 50.3 ng/L, the IgG content was 9.65 g/L, the IL-1β content was 0.135 mg/L, and the IL-6 content was It is 23.56 ng/L.

Example 23 A method for preparing a medicament for treating rheumatoid rheumatoid arthritis:

Step 1, weighing

Weigh the marine algae glycoprotein and each Chinese medicine ingredient according to the formula;

Step 2, Chinese medicine leaching

(1) Cleaning

Wash each Chinese medicine ingredient with water to remove impurities;

(2) pulverization, microwave extraction

The traditional Chinese medicine is pulverized into 100 mesh medicinal material powder, 10 times of 50% ethanol is added, the temperature is controlled to 60 ° C, microwave irradiation with 260 W microwave power, microwave wavelength of 130 mm, frequency of 1200 MHz for 5 min, filtration, and the filtrate is collected;

Separating the dregs, adding 12 volumes of clean water, controlling the temperature to 50 ° C, using microwave power of 200 W, microwave wavelength of 140 mm, microwave irradiation at a frequency of 1250 MHz for 5 min, filtering, collecting the filtrate;

The filtrates were combined twice; filtered through a 0.45 μm microporous membrane to obtain a filtrate. The obtained filtrate was introduced into a double flow spiral nozzle of a Büchi290 small spray dryer via a peristaltic pump, and the inlet temperature was controlled at 125 ° C, and the feed rate was 3 mL / Min, spray drying to obtain a traditional Chinese medicine powder.

Step 3. Add marine algae glycoprotein

The marine algae glycoprotein powder and the above traditional Chinese medicine powder are uniformly mixed to prepare different dosage forms such as capsules and tablets.

The medicament of the present invention has a pH of between 5.3 and 9.8, preferably between 6.5 and 7.5.

The invention has been subjected to a large number of tests, and the invention has been carried out by performing a plurality of tests on a mixture of marine shells, bones of livestock and poultry, glycoprotein extracted from the skeleton of marine animals, and polysaccharides and proteins.

Embodiment 24 A medicament for treating rheumatoid rheumatoid

The drug is a mixture of polysaccharides and proteins;

The drug, in parts by weight, comprises 1-99% polysaccharide, 1-99% protein;

The polysaccharide comprises: glucose, mannose, rhamnose, galactose;

The protein comprises: asparagine, cysteine, lysine, arginine, serine, threonine, alanine, aspartic acid, glutamine, glutamic acid, histidine, Isoleucine, glycine, leucine, methionine, phenylalanine, valine, tyrosine, valine.

The polysaccharide and protein mixture, the polysaccharide has a molecular weight of 0.2-3000 kDa, and the protein has a molecular weight of 0.2-3000 kDa.

a mixture of the polysaccharide and the protein, further a mixture of an algal polysaccharide and an algal protein;

a mixture of the algal polysaccharide and the algal protein, further comprising a pigment;

The pigment is a natural pigment contained in an algae substance;

The algal protein may be phycocyanin, phycoerythrin or phycoerythrin.

The glycoproteins include synthetic glycoproteins and synthetic polysaccharides and proteins.

The drug of the invention has a non-toxic dose of 1.6 g/kg for oral administration for dogs for 12 weeks, which is equivalent to 50 times of the equivalent dose for humans, so the safety of the clinical test can be considered to be guaranteed.

The medicament of the present invention may also be a health care product or a food.

The basic principles and main features of the present invention and the advantages of the present invention are shown and described above. It should be understood by those skilled in the art that the present invention is not limited by the foregoing embodiments, and that the present invention is only described in the foregoing description and the description of the present invention, without departing from the spirit and scope of the invention. Various changes and modifications are intended to be included within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and their equivalents.

Claims (10)

1. A medicament for treating rheumatoid rheumatoid, characterized in that the medicament is a glycoprotein or a mixture or polypeptide or protein of a polysaccharide and a protein.
2. A medicament for treating rheumatoid rheumatoid according to claim 1, wherein the medicament is a marine algae glycoprotein.
3. A medicament for treating rheumatoid rheumatoid according to claim 2, wherein said glycoprotein comprises, by weight, 1-99% sugar, 1-99% protein; said marine algae sugar The protein, by weight, comprises 1-99% sugar, 1-99% protein; a mixture of the polysaccharide and protein, including 1-99% sugar, 1-99% protein by weight.
4. A medicament for treating rheumatoid rheumatoid according to claim 2, wherein said glycoprotein has a molecular weight of 0.2 to 3000 kDa; said marine algal glycoprotein has a molecular weight of 0.2 to 3000 kDa; said polysaccharide and A mixture of proteins, the molecular weight of the polysaccharide is 0.2-3000 kDa, and the molecular weight of the protein is 0.2-3000 kDa.
5. A medicament for treating rheumatoid rheumatoid according to claim 1, characterized in that it comprises, by weight, 1-99 parts of glycoprotein and 1-23 parts of glucuronic acid.
6. A medicament for treating rheumatoid rheumatoid according to claim 1, which comprises, by weight, 1-99 parts of glycoprotein, 1-23 parts of glucuronic acid, and 3-11 parts of barley.
7. The medicament for treating rheumatoid rheumatoid according to claim 1, wherein the algae is one or more of cyanobacteria, green algae, red algae, gold algae, and brown algae.
8. A medicament for treating rheumatoid rheumatoid according to claim 1, characterized in that it comprises, by weight, 1-99 parts of glycoprotein, 5-13 parts of medlar, 6-14 parts of moxibustion licorice, and glucose aldehyde. 1-17 parts of acid.
9. The medicament for treating rheumatoid rheumatoid according to claim 1, characterized in that: by weight content, 1-99 parts of glycoprotein, 5-13 parts of barley, 6-14 parts of moxibustion, and Corydalis 7 -12 parts, forsythia 5-10 parts.
10. A medicament for treating rheumatoid rheumatoid according to any one of claims 5-9, characterized in that the glycoprotein, marine algae glycoprotein comprises, by weight, 1-99% sugar, protein 1-99%.